Interventions for H1N1 Influenza: cost-effectiveness
Citation: Pasquini-Descomps H, Brender N, Maradan D. Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions. Value in Health 2017; 20: 819-27
What is this? The COVID-19 pandemic is placing a great strain on health systems and economies. Information on the cost-effectiveness of interventions used in other pandemics might help those making decisions about interventions for COVID-19.
In this systematic review, the authors searched for studies that presented cost-effectiveness or cost-benefit analyses for A/H1N1 pandemic interventions. They did their search in December 2014. They identified 18 studies that assessed the cost-effectiveness of 12 different strategies. All studies examined costs from a societal perspective.
What was found: Hospital quarantine, vaccination and use of an antiviral stockpile were highly cost-effective for the A/H1N1 pandemic, but it is uncertain whether these findings are applicable to the COVID-19 pandemic.
School closures, antiviral treatments and social distancing may not have been cost-effective in the H1N1 pandemic, but it is uncertain whether these findings are applicable to the COVID-19 pandemic.
Disclaimer: This summary has been written by staff and volunteers of Evidence Aid in order to make the content of the original document accessible to decision makers who are searching for the available evidence on the coronavirus (COVID-19) but may not have the time, initially, to read the original report in full. This summary is not intended as a substitute for the medical advice of physicians, other health workers, professional associations, guideline developers, or national governments and international agencies. If readers of this summary think that the evidence that is presented within it is relevant to their decision-making they should refer to the content and details of the original article, and the advice and guidelines offered by other sources of expertise, before making decisions. Evidence Aid cannot be held responsible for any decisions made about the coronavirus (COVID-19) on the basis of this summary alone.